Oppenheimer raised the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $21 and keeps an Outperform rating on the shares. The firm hosted management for an investor call ahead of Q2 readout, wherein management described Entrada’s endosomal escape platform that has delivered differentiated data. Oppenheimer continues to see the company’s platform as potentially best-in-class and believes Q2 readout could drive 50% or more upside.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Entrada Therapeutics management to meet with Oppenheimer
- Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
- Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
- Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)